Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01522664 (Clinical Trial / DEDN6526A / RG7636)

Study Title
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma (NCT01522664)

Trial Description
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A (also known as RG7636) in patients with metastatic or unresectable melanoma. Cohorts of patients will receive escalating doses of DEDN6526A by intravenous infusion on Day 1 of each 21-day cycle. In the absence of disease progression or unacceptable toxicity, patients may continue to receive DEDN6552A for up to 17 cycles (1 year) This trial is sponsored by Genentech, Inc.[1]

Study Data

  • Condition: Malignant Melanoma
  • Interventions:
    • Drugs used in this trial
      • DEDN6526A (RG7636)
  • Phase: I
  • Enrollment: 53
  • Start: March 2012
  • Estimated Completion: April 2015
  • Last verified: April 2015

Study Schematic 

(Coming soon)


Last Editorial review: September 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar